Arrowhead Pharmaceuticals (ARWR) 10-K2017 FY Annual report

Filed: 12 Dec 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accrual, acute, adaptive, affinity, AMG, Article, assembly, ATO, authorisation, bar, breakdown, breakthrough, Brexit, buildup, calendar, cardio, catalytic, Century, chylomicron, chylomicronemia, Computershare, conceptual, coordinate, coronary, Council, CTA, EC, edema, endothelial, endpoint, expedite, familial, Fast, fatal, FCS, formally, GCC, GCP, Gulf, harmonised, hereto, HHS, Hyperlipidemia, hypertriglyceridemia, inadvertent, inhaled, Inspector, interpreted, irreversible, judgement, Junior, laryngeal, laying, leave, leaving, Lebanon, linker, lipase, messenger, modification, monkey, motion, neurodegenerative, obstruct, outset, pair, pharmacovigilance, philosophy, political, portal, prevalence, primarly, rarity, recurrent, refocused, refocusing, regime, rejected, repeal, rich, rodent, rolling, simpler, Singh, sophisticated, speaking, stayed, stored, stranded, streamline, stringent, Supplementary, surrogate, syndrome, tailored, tender, threatening, Track, transparency, Treaty, triglyceride, TRiM, TRiMTM, true, Trust, UK, Unz, Uruguay, variation, verify, veterinary, violate, VLDL, withdrawn

Removed: abandonment, Adipotide, adjusted, advancing, aggregate, bearing, beneficially, calculating, collected, convertible, coupon, digit, dissolution, earned, employ, encoded, forego, genome, Greece, Homing, indefinite, induced, INEX, inflow, intranuclear, labile, led, lived, man, Marsh, mice, obesity, outdated, pari, passu, pH, plaintiff, polyampholyte, Portugal, remain, repeated, requisite, resulted, Rice, safeguarding, showed, step, transition, Turkey, Unidym, vector, vote, whistleblower, willfully, William

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ARWR transcripts

ARWR similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Forms S-3 (Nos. 333-202737, 333-193748, 333-191922, 333-188718, 333-178532, 333-178073, 333-178072, 333-176159, 333-164039, 333-161344, 333-148218, 333-144109, 333-137329, 333-132310, 333-124065, 333-113065, 333-213484, 333-214311, and 333-214315) and Forms S-8 (Nos. 333-202741, 333-198920, 333-194596, 333-190970, 333-180692, 333-170252, 333-136225, 333-124066, 333-120072, and 333-210117) of Arrowhead Pharmaceuticals, Inc. of our report dated December 12, 2017, with respect to the consolidated balance sheets of Arrowhead Pharmaceuticals, Inc. and Subsidiaries as of September 30, 2017 and September 30, 2016, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity and cash flows for each of the years in the three-year period ended September 30, 2017, and the effectiveness of internal control over financial reporting as of September 30, 2017, which reports appear in the September 30, 2017 annual report on Form 10-K of Arrowhead Pharmaceuticals, Inc.

/s/ Rose, Snyder & Jacobs LLP

Encino, California

December 12, 2017